Holen Sie sich die Stockscreener-App
50.26
1.68%
-0.86
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$51.12
Offen:
$51.57
24-Stunden-Volumen:
2.14M
Relative Volume:
1.56
Marktkapitalisierung:
$5.93B
Einnahmen:
$3.22M
Nettoeinkommen (Verlust:
$-576.40M
KGV:
-9.342
EPS:
-5.38
Netto-Cashflow:
$-407.05M
1W Leistung:
+8.88%
1M Leistung:
+9.69%
6M Leistung:
-11.17%
1J Leistung:
-34.30%
1-Tages-Spanne:
$48.88
$51.74
1-Wochen-Bereich:
$45.05
$51.74
52-Wochen-Spanne:
$40.53
$81.36
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie CYTK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
50.26 | 5.93B | 3.22M | -576.40M | -407.05M | -5.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-07 | Eingeleitet | Citigroup | Buy |
| 2025-01-22 | Eingeleitet | Stifel | Buy |
| 2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Cytokinetics (CYTK) Projected to Post Earnings on Tuesday - MarketBeat
Allspring Global Investments Holdings LLC Has $4.11 Million Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Van ECK Associates Corp - MarketBeat
Cytokinetics, Incorporated (CYTK): One of the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - MSN
Insider Sell: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Fady Ibraham Malik Sells 2,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - MarketBeat
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Inside Cytokinetics' Latest Employee Compensation Strategy: $46.16 Stock Options and RSU Details Revealed - StockTitan
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Bought by Peregrine Capital Management LLC - MarketBeat
Cytokinetics EVP sells $91,960 in stock By Investing.com - Investing.com South Africa
Stifel maintains Buy on Cytokinetics stock, target at $80 By Investing.com - Investing.com Canada
Cytokinetics EVP sells $91,960 in stock - Investing.com
Cytokinetics (NASDAQ:CYTK) Stock Price Up 7.6%Time to Buy? - MarketBeat
Cytokinetics stock touches 52-week low at $41.69 amid market challenges - MSN
Cytokinetics (NASDAQ:CYTK) Upgraded by Morgan Stanley to "Overweight" Rating - MarketBeat
Cytokinetics jumps amid renewed takeover speculation - MSN
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study - MSN
Cytokinetics (NASDAQ:CYTK) Reaches New 1-Year LowHere's What Happened - MarketBeat
Harvey Capital Management Inc. Acquires Shares of 22,105 Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics upgraded by Morgan Stanley on upside potential - MSN
Morgan Stanley Upgrades Cytokinetics (CYTK) - MSN
Cytokinetics to Announce Fourth Quarter Results on February 27, 2025 - EIN News
Morgan Stanley Upgrades Cytokinetics to Overweight From Equalweight, Trims Price Target to $67 From $70 - Marketscreener.com
This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Morgan Stanley lifts Cytokinetics stock rating, cuts target to $67 - MSN
Morgan Stanley lifts Cytokinetics stock rating, cuts target to $67 By Investing.com - Investing.com UK
Cytokinetics adds pharma veteran Landry to board ahead of drug launch - Investing.com Nigeria
Cytokinetics' (CYTK) "Market Outperform" Rating Reaffirmed at JMP Securities - MarketBeat
Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Citigroup - MarketBeat
Cytokinetics Names Robert E. Landry to Board of Directors - GlobeNewswire
Cytokinetics adds pharma veteran Landry to board ahead of drug launch By Investing.com - Investing.com South Africa
Cytokinetics Appoints Robert E. Landry to Board - TipRanks
Cytokinetics Names Robert E. Landry To Board Of Directors -February 11, 2025 at 07:53 am EST - Marketscreener.com
Cytokinetics Appoints Robert E. Landry to Board of Directors to Enhance Financial and Operational Expertise as Company Prepares for Commercialization - Nasdaq
abrdn plc Acquires 102,457 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics (NASDAQ:CYTK) Sets New 12-Month LowShould You Sell? - MarketBeat
JMP Securities maintains Cytokinetics stock with $78 target - MSN
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cytokinetics Inc-Aktie (CYTK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Feb 18 '25 |
Sale |
45.98 |
2,000 |
91,960 |
116,071 |
| Malik Fady Ibraham | EVP Research & Development |
Feb 04 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
118,071 |
| Malik Fady Ibraham | EVP Research & Development |
Feb 04 '25 |
Sale |
48.06 |
2,000 |
96,120 |
116,071 |
| Malik Fady Ibraham | EVP Research & Development |
Jan 21 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
118,071 |
| Malik Fady Ibraham | EVP Research & Development |
Jan 21 '25 |
Sale |
45.92 |
2,000 |
91,840 |
116,071 |
| Malik Fady Ibraham | EVP Research & Development |
Jan 07 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
118,071 |
| Malik Fady Ibraham | EVP Research & Development |
Jan 07 '25 |
Sale |
49.32 |
2,000 |
98,640 |
116,071 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):